CIBUS INC
CBUSNASDAQTrading Snapshot
- Day Range
- $1.53 – $1.56
- 52-Week Range
- $1.09 – $4.19
- Volume
- $2.80B
- Avg Volume
- $2.10B
- Shares Outstanding
- 76.3M
- Next Earnings
- Nov 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $994,000
- P/E Ratio
- -0.9
- P/S Ratio
- 25.8x
- EPS (TTM)
- $-1.28
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +90.3%
Why Investors Own CBUS
- ✓High-growth profile — revenue up +2.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 70% gross margin and 4% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CIBUS INC
CBUS
StockOtter · stockotter.spaceAbout CIBUS INC
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Cibus and Crystal Crop Protection Team Up to Improve India's Mustard Crop
Collaboration pairs Cibus' platform for improving a plant's own genes with Crystal Crop's mustard varieties and its reach across India, with the goal of putting better-performing seed in growers' hands in a fraction of t
Cibus, Inc. (CBUS) Q2 2026 Earnings Call Transcript
Cibus, Inc. (CBUS) Q2 2026 Earnings Call Transcript
Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates
Cibus (CBUS) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.61 per share a year ago.
Cibus Q2 Earnings Call Highlights
Cibus NASDAQ: CBUS reported second-quarter 2026 revenue of $1.0 million, compared with $0.9 million a year earlier, as the agricultural biotechnology company advanced its Sustainable Ingredients program and updated the e
Cibus Reports Second Quarter Financial Results and Provides Business Update
Commercialization execution advances in Rice and Sustainable Ingredients United States and European Union now aligned on generally treating crops with no added foreign DNA as conventionally bred Quarterly net cash usage
Cibus to Report Second Quarter 2026 Financial Results on August 13, 2026 After the Market Close and Host Conference Call
SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a technology company that helps farmers grow more food with fewer inputs, today announced that the company will report second quarter 2026 financia